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Abstract
Improved detection of anti-carbohydrate antibodies is a need in clinical identification of biomarkers for cancer cells or
pathogens. Here, we report a new ELISA approach for the detection of specific immunoglobulins (IgGs) against
carbohydrates. Two nanometer gold glyconanoparticles bearing oligosaccharide epitopes of HIV or Streptococcus
pneumoniae were used as antigens to coat ELISA-plates. A ~3,000-fold improved detection of specific IgGs in mice
immunized against S. pneumoniae respect to the well known BSA-glycoconjugate ELISA was achieved. Moreover,
these multivalent glyconanoparticles have been employed in solid phase assays to detect the carbohydrate-
dependent binding of human dendritic cells and the lectin DC-SIGN. Multivalent glyconanoparticles in ELISA provide
a versatile, easy and highly sensitive method to detect and quantify the binding of glycan to proteins and to facilitate
the identification of biomarkers.
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Introduction
The detection of anti-glycan antibodies in serum is of
mounting interest for the evaluation of carbohydrate-based
vaccines and pathogen infection as well as for the detection of
biomarkers in diseases like cancer. The profiling of human
serum antibodies has shown that a substantial part of
circulating antibodies is directed against carbohydrates [1]. The
affinity of anti-carbohydrate antibodies towards their epitopes,
demands a multivalent presentation of the carbohydrate-
ligands and highly sensitive screening methods. Furthermore,
the low abundance of anti-carbohydrates antibodies in serum
during pathological states and/or early infection hampers their
use as biomarkers for prompt diagnosis. The coupling of
carbohydrates on a scaffold (carrier) allows the multiple
presentation of these antigens in an enzyme-linked
immunosorbent assay (ELISA) [2]. However, while protein
coating of ELISA plates is a well-established methodology,
equivalent strategies for the direct coating of carbohydrates
have been hampered by technical limitations. Early attempts to
detect antibodies against bacterial polysaccharides by ELISA
showed the difficulty to absorb carbohydrates to the supporting
materials. This problem was solved by conjugation of the
polysaccharides to positive charged poly-lysine scaffold, which
allowed the immobilization of the resulting neoglycoconjugate
to ELISA plates [3]. Soon afterwards, glycolipids were
effectively employed to coat ELISA surfaces for a
Mycobacterium leprae-specific serodiagnostic test [4–6]. With
the identification and characterization of oligosaccharide
antigen structures, chemical strategies were developed to
conjugate the carbohydrate antigen to proteins (bovine or
human serum albumin), polymers (acrylamide derivatives) [7,8]
and dendrimers [9] in order to enhance the number
carbohydrate epitopes on the ELISA surface and improve the
sensitivity of the assay. The relatively recent introduction of
glycan microarray technology also provided a platform for high
throughput screening, yielding information about the specificity
of glycan-binding proteins [10,11]. Although novel applications
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of glycan microarrays are emerging, including vaccine
development and identification of disease specific biomarkers,
ELISA is still the most widely used assay for diagnostic
purposes. Its simplicity, sensitivity and low cost make ELISA a
reliable competitor of newer screening methods for diagnosis
such as printed glycan microarray technology. Although the
comparison between glycan microarrays technology and
conventional ELISA for evaluation of anti-carbohydrate
antibodies led to contrasting opinions about sensitivity [9,12]
the importance of both techniques as complementary
screening methods has prompted the development of new
immobilization strategies to improve their performance. For
example, a new type of microarray based on silica
glyconanoparticles has recently been described to study
glycan-lectin interactions [13]. Here we describe the
development of a fast and highly sensitive method, in which
commercially available ELISA plates are directly coated with
two nanometer gold glyconanoparticles (GNPs) [14] carrying
carbohydrate antigens. We demonstrate that anti-carbohydrate
antibodies can be detected in the nanomolar range by
performing GNP-ELISA with the purified anti-HIV human
monoclonal antibody 2G12 and with serum from mice
immunized against Streptococcus pneumoniae. Moreover, we
show that GNPs can be employed in a solid phase assay to
profile the carbohydrate-binding of human cells and to profile
lectins affinities on a highly multivalent surface. GNPs allow the
introduction of a high number of carbohydrates on a
nanometric gold scaffold [14] and the combination of different
molecules on the same nanoparticle in a controlled way and
with varying density [15,16]. We reasoned that the high number
of carbohydrates on the GNPs (60-100 molecules) and their
high molecular weight (around 50 kD) make GNPs very
suitable for the ELISA plate coating in order to improve the
sensitivity of the anti-carbohydrate antibody detection and
study other carbohydrate-binding proteins.
Materials and Methods
Materials
All chemicals were purchased as reagent grade from Sigma-
Aldrich, except chloroauric acid (Strem Chemicals), and were
used without further purification. Anti HIV-1 gp120 Monoclonal
Antibody 2G12 was kindly supplied by Dr D. Katinger (Polymun
Scientific, Vienna, Austria).
Preparation of GNPs
GNPs were prepared in a one-step reaction by reducing a
gold salt with sodium borohydride in the presence of a mixture
of thiol-functionalized glycoconjugates in the desired molar
ratio following an established procedure [17]. GNPs bearing
10% of a thiol-ending conjugate of dimannoside Man(α1-2)
Man(α1→) (DiMan), tetramannoside Man(α1-2) Man(α1-2)
Man(α1-3) Man(α1→) (TetraMan) or Man(α1-2) Man(α1-3)
[Man(α1-2) Man(α1-6)] Man(α1→) (PentaMan) and 90% of 5-
(mercapto)pentyl β-D-glucopyranoside as inner component
were prepared as previously reported [18]. GNPs carrying
Gal(β1-4) Glc(β1-6) [Gal(β1-4)] GlcNAc(1→) (TetraPn) and
OVA323-339 peptide were prepared following a protocol
previously described [19]. The ratio of the different ligands on
the nanocluster surface was determined by quantitative 1H
NMR. Transmission electron microscopy showed an average
gold core diameter of 2 nm.
GNP-ELISAs
50 µL of a GNPs solution of 25µg/mL (or the reported
concentration in the manuscript) in buffer (50mM Na 2CO3,
pH=9.7) were used to coat the Nunc MaxiSorp plate overnight
at 4°C or 2h at room temperature. After discarding the GNPs
solutions and washing with PBS (10mM, pH=7.4) (2x200µL),
the wells were blocked with 200µL of 1% BSA (Sigma-Aldrich,
lyophilized powder, ≥96%, agarose gel electrophoresis) in PBS
at room temperature for 30 min. The blocking solution was
discarded and 100µL of 2G12 (from 13.8 to 0.13nM) or 100µL
of mice serum at different dilution in assay buffer (0.5% BSA)
were added to the plate. After shaking for 1 h at 500rpm, the
wells were washed with PBS (3x200µL) and then 100 µL of
anti-human horseradish peroxidase (0.8 µg/mL, life
technologies, Novex® Goat anti-Human IgG-HRP) or 100 µL of
anti-mouse horseradish peroxidase (0.8 µg/mL, life
technologies, Novex® Rabbit anti-Mouse IgG-HRP) were added
for 2G12 or mice serum IgG detection, respectively. After 30
min of shaking at 500 rpm, the wells were washed with PBS
(3x200µL). Finally, 100 µL of substrate solution (3,3′,5,5′-
Tetramethylbenzidine, TMB, in citric/acetate buffer, pH=4, and
H2O2) was added and after 3 min incubation at room
temperature the reaction was stopped with 50 µL of H2SO4 (0.8
M) and the optical density was measured at 450 nm in an
ELISA reader. These experiments were always performed in
triplicate with independently prepared samples.
In vitro generation and culture of human DCs
Immature DCs were generated from human peripheral blood
mononuclear cells (PBMCs) as described previously [20] from
buffy coats of healthy volunteers. The peripheral blood of
healthy volunteers was used for isolation of PBMCs upon
donor consent in accordance with the Declaration of Helsinki
(Sanquin Blood bank, Amsterdam, The Netherlands). The
Sanquin’s General Terms and Conditions can be founded
following this link: http://www.sanquin.nl/repository/
documenten/en/general-conditions/sanquin-blood-supply-
general-terms-and-conditions-of-purchase-EN.pdf.
The Ethical Advisory Council of Sanquin can be checked
following this link: http://www.sanquin.nl/en/about/about-
sanquin/organisation/advisory-councils/ethical-advisory-
council/.
Monocytes were prepared from PBMCs by centrifugation
over Percoll and incubated for 5 days in RPMI supplemented
with 10% heat inactivated fetal calf serum, 2.4 mM L-glutamine,
100 U/mL penicillin-streptomycin (all from Gibco), 800 U/mL of
human recombinant granulocyte-macrophage colony-
stimulating factor and 500 U/mL of human recombinant IL-4
(both from Schering-Plough, Brussels, Belgium).
Cellular binding
Ninety-six-well plates (Nunc MaxiSorp®) were coated at room
temperature for 2 h with 50 µL of GNPs (25 μg/mL) and
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afterwards blocked with 1% BSA. Calcein (calceine AM,
Molecular Probes) was used to label moDC following a
reported protocol [21]. Calcein labeled moDC were incubated
on the GNPs-coated ELISA wells (40,000 cells/well) for 2 h at
37°C in calcium and magnesium containing TMS buffer (20 mM
tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 8.0; 150 mM
NaCl; 1 mM CaCl2; 2 mM MgCl2) in presence or absence of
3.75 mM EGTA or 10 μg/mL of mAbs AZN-D1. Non adherent
cells were then removed by gentle washing with 0.5% BSA-
PBS solution and the adherent cells on the plate were lysed
and the binding was correlated with the calcein absorption. The
fluorescence was quantified on a Fluorostar spectrofluorimeter
(BMG Labtech, Offenburg, Germany).
DC-SIGN binding
Nunc MaxiSorp plates were coated with 50 μL GNPs (15
μg/mL in coating buffer) for 2 h at room temperature. The wells
were washed twice with TMS (2x200μL) and blocked with 100
μL TMS with 1% of BSA for 30 min at room temperature. After
1x200μL wash with PBS, the wells were incubated at 37°C with
50 μL DC-SIGN-Fc (3 μg/mL) in TMS with 1% of BSA for 1 h.
The wells were washed four times with TMS (4x200μL) and
incubated at room temperature with 50 μL of Goat-anti human
HRP (0.8 μg/mL) in TMS with 1% of BSA for 30 min. After four
washes with TMS (4x200μL), 100 µL of substrate solution (3,3′,
5,5′-Tetramethylbenzidine, TMB, in citric/acetate buffer, pH=4,
and H2O2) were added and after 4 min at room temperature the
reaction was stopped with 50 µL of H2SO4 (0.8M) and the plate
was read at 450 nm ELISA reader. All the experiments were
performed in triplicate.
Statistical methods
Multiple t-test was used to determine differences between
the experiments and the control conditions. p-value ≤0.05 is
considered to be statistically significant (Graphad Prism 6.00).
One asterisk indicates a p-value < 0.05; two asterisks indicate
a p-value < 0.01 and three asterisks indicate a p-value < 0.001.
Results and Discussion
To validate the GNP-ELISA we have selected as antigens a
panel of GNPs (Figure 1) that we have previously prepared to
investigate glycan/protein interactions and as a carrier for
carbohydrate-based vaccine candidates: Two of them (Figure
1A) carry the disaccharide Man(α1-2) Man(α1→) (DiMan-GNP)
or the tetrasaccharide Man(α1-2) Man(α1-2) Man(α1-3)
Man(α1→) (TetraMan-GNP) that are present in the high-
mannose type glycans of HIV glycoprotein gp120 [18]. Another
set (Figure 1B) is formed by GNPs that carry the
tetrasaccharide Gal(β1-4) Glc(β1-6) [Gal(β1-4)] GlcNAc(1→)
epitope of the S. pneumoniae type 14 polysaccharide, alone
(TetraPn-GNP) or in combination with the small peptide
OVA323-339 of ovalbumin (TetraPnOv-GNP) [19]. As a control
(Figure 1C), GNPs bearing only glucose (Glc-GNP) or
galactose (Gal-GNP) were also included. The oligosaccharides
are conjugated to the same aglycon, a thiol-ending amphiphilic
linker to attach them to the gold surface. A glucose conjugate is
incorporated as inner component to modulate the density of the
antigenic oligosaccharides on the surface [22]. Nunc MaxiSorp
plates were selected for the GNP-ELISA, as similar modified
polystyrene slides were previously used to prepare microarrays
of polysaccharides and proteoglycans [23]. GNPs were
adsorbed on the MaxiSorp surface due to their high
hydrophilicity.
Detection of anti-HIV monoclonal antibody 2G12
As a proof of principle, we set up a GNP-ELISA for the
detection of the anti-HIV human monoclonal antibody 2G12.
The 2G12 antibody is one of the broadly neutralizing antibodies
against HIV-1 and binds to a conserved high-mannose cluster
on HIV gp120 [24]. GNPs carrying selected gp120 high-
mannose oligosaccharides were previously shown to bind
2G12 and to compete with 2G12/gp120 binding as
demonstrated by surface plasmon resonance (SPR), NMR, and
cellular neutralization experiments [25]. In particular, TetraMan-
GNPs were able to bind 2G12 with high avidity (nanomolar
range) and inhibit 2G12/gp120 interaction in the micromolar
range as measured by SPR and NMR. On the contrary, the
analogue DiMan-GNPs did not show significant binding to
2G12 even at higher concentration [25]. For this reason, in the
present study, we selected TetraMan-GNP for the detection of
2G12 and DiMan-GNP as control to exclude non-specific
interactions.
Following the standard procedure for ELISA antigens
coating, the wells were coated with a solution of TetraMan-
GNP, DiMan-GNP, and Glc-GNP at different concentrations
(100, 10, and 1 µg/mL). Glc-GNP was included as a negative
control. We observed in our experiments that multiple Tween
washes decreased the sensitivity of the detection (data not
shown), so we decided to wash the plate with PBS (10 mM, pH
7.4) before blocking with 1% BSA. Next, 2G12 was added at
2.4 µg/mL (16.5 nM) concentration and incubated for 1 h at
room temperature followed by detection with horseradish
peroxidase (HRP)-conjugated goat anti-human IgG.
Figure 2A shows the concentration-dependent response of
2G12 towards the GNPs measuring the optical density (OD) at
450 nm. Even at 1 µg/mL of coating, TetraMan-GNP was able
to induce a significant signal (OD ~ 0.5) after incubation with
2G12. However, 2G12 did not interact with the DiMan-GNP at
the tested concentrations. The negative response of the
DiMan-GNP excluded non-specific interactions (due to the
linker or gold) between 2G12 and the gold nanoparticles.
Glc-GNP was not recognized by the antibody (Figure 2)
excluding also non-specific interactions because both
TetraMan-GNP and DiMan-GNP have 90% of Glc conjugate on
their surface. 2G12 recognized neither GNPs coated with
OVA323-339 nor GNPs bearing a branched high-mannose
pentasaccharide (Figure S1 in File S1; for the structures of
PentaMan-GNP and OVA/Glc-GNP, see Figure S6 in File S1).
When the monomeric TetraMan oligosaccharide conjugated
to 2-aminoethyl linker was employed to coat the Nunc
MaxiSorp plate under the same conditions as those for GNPs
coating, no 2G12 response was detected (data not shown).
GNPs with increasing density of TetraMan (50%) led to a more
sensitive 2G12 detection in comparison to the 10% TetraMan-
GNP at the same concentration (25 µg/mL) (Figure S2 in File
A Solid Phase Assay Based on Glyconanoparticles
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S1). The 50% TetraMan-GNP contains 3 times more
mannosides at the same mg/mL concentration (Text S1 in File
S2).
These results suggest that the multivalent presentation of the
oligomannosides on the gold nanoparticles, used as antigens
in the ELISA coating, provides high selectivity and sensitivity
for the detection of 2G12.
To get a deeper insight on the sensitivity of the GNP-ELISA,
20 µg/mL of GNPs were used to coat the ELISA plates and
different concentrations of 2G12 (from 13.8 nM to 0.1nM) were
Figure 1.  Gold glyconanoparticles used in this work to coat ELISA plates for anti-carbohydrate-antibodies detection.  (A)
High-mannose type undecasaccharide present on the HIV gp120 surface and GNPs carrying the tetramannoside (TetraMan) or
dimannoside (DiMan), partial structures of the viral gp120 high-mannose undecasaccharide, to detect 2G12 antibody. (B) Repeating
unit of S. pneumoniae type 14 capsular polysaccharide and GNPs carrying the tetrasaccharide epitope (TetraPn) of the S.
pneumoniae Pn14PS and the T-helper OVA323-339. (C) GNPs carrying glucose or galactose as control.
doi: 10.1371/journal.pone.0073027.g001
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subjected to analysis (Figure 2B). The GNP-ELISA with
TetraMan-GNP allowed the detection of 2G12 at 1.4 nM (0.2
µg/mL). Considering that the concentration of 2G12 in plasma
(in animal models) ranges between 1200 to 49 µg/mL [26], our
results indicated that GNP-ELISA is a valid method for the
detection of very low levels of anti-carbohydrate antibodies that
could be also applied for biological samples. Our GNPs add a
new multivalent tool to the described glycan arrays of
covalently coupled oligomannose dendrons [9] and to the virus
capsides oligomannoside conjugates used in ELISA as
antigens [27] for 2G12 detection. The detection limit in the
glycans array with the dendrons [9] or in the conventional
ELISA plates with the virus conjugates [27] is 0.05 and 0.5
μg/mL, respectively, while the GNP-ELISA is able to detect
0.2μg/mL of 2G12.
GNP-ELISA for the detection of anti-carbohydrates
antibodies in mice
The next step was to verify the method for the detection of
anti-carbohydrate IgG antibodies in a more complex biological
sample. We have previously demonstrated that TetraPnOv-
GNP bearing a 40% of the synthetic epitope TetraPn, which
corresponds to the single repeating unit of the S. pneumoniae
type 14 capsular polysaccharide (Pn14PS) [28], and a 5% of
the T-cell epitope OVA323-339 (Figure 1) are able to evoke
functional anti-carbohydrate IgG antibodies in mice against
Pn14PS [19]. In that work, the detection of the specific IgGs
was performed by coupling the tetrasaccharide epitope (Tetra-
Pn) to BSA and running a “classic” ELISA for IgG antibodies
diluting mice sera from 1:10 to 1:1000. Here, TetraPnOv-GNP
(25 µg/mL) was directly used to coat ELISA plates for the IgG
detection (Figure 3). TetraPn-GNP carrying 50% of
tetrasaccharide and 50% glucose was also tested in the ELISA
in order to exclude sera interactions with the OVA323-339 peptide.
TetraMan-GNP, DiMan-GNP, Glc-GNP, and Gal-GNP were
used as control. Sera from mice immunized with TetraPnOv-
GNP were diluted 1:30,000. Specific IgGs against TetraPn
recognized TetraPnOv- and TetraPn-GNPs on the ELISA plate
with high OD at 450 nm (Figure 3A). High levels of IgGs were
detected in serum of mice immunized with the TetraPnOv-GNP
(OD > 1) and significant signal (~0.8 OD) was also detected for
TetraPn-GNP. GNPs bearing 5% of OVA peptide and 95% of
glucose were not detected by mice sera IgGs (Figure S3 in File
S1).
No response was detected after coating the ELISA plate with
Glc-GNP, indicating the absence of significant titers of anti-
glucose antibodies in the serum of mice immunized with the
TetraPnOv-GNP (that contains 50% of glucose). A weak
positive but significant signal (OD > 0.2) was observed for Gal-
GNP, in agreement with the molecular structure of the
biantennary TetraPn (Figure 1) that presents a terminal
galactose in both antennas. As expected, serum antibodies
showed no affinity for mannosides, as both TetraMan- and
DiMan-GNPs were not able to capture any component of sera
from mice immunized with TetraPnOv-GNP. The presence of
specific IgGs against TetraPn was also detected in mice
immunized with Pn14PS conjugated to cross reactive material
from diphtheria toxin (Pn14PS-CRM) [19] (Figure S4 in File
S1). Sera from mice immunized with saline were used as
negative control and gave no signal (OD <0.2) in the GNP-
ELISA (Figure 3A). The secondary anti-mouse IgG antibody did
Figure 2.  Detection of anti-HIV monoclonal antibody 2G12 by GNP-ELISA.  (A) TetraMan, DiMan and Glc-GNP at different
concentrations (100, 10, and 1 µg/mL) were used for ELISA plates coating. Antibody 2G12 (2.4 µg/mL, 16 nM) recognizes
TetraMan-GNP in a coating-concentration dependent manner, while DiMan-GNP and Glc-GNP are not recognized. Differences
between TetraMan-GNP and both control GNPs are significant, as indicated with two asterisks (p<0.01). (B) Limit of 2G12 detection
with TetraMan-GNP: 20 µg/mL of GNPs were used to coat the plate and subsequently incubated with different concentrations of
2G12 (13.8 to 0.1 nM). Error bars represent the standard deviation of three different experiments. Differences between TetraMan-
GNP and both control GNPs are significant, as indicated with three asterisks (p<0.001). Background signal due to non-specific
interactions was around OD 0.25.
doi: 10.1371/journal.pone.0073027.g002
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not react with any of the GNPs, so that non-specific
interactions were excluded.
Serial dilutions (1:10,000 to 1:100,000) of sera from mice
immunized with TetraPnOv-GNP were analyzed on plates
Figure 3.  GNP-ELISA for the detection of anti-carbohydrates antibodies from mice immunized with TetraPnOv-GNP.  (A)
Detection of specific IgG by GNPs carrying different carbohydrates. TetraPnOv- and TetraPn-GNPs show strong binding to mice
serum at a 1:30,000 dilution. Detectable binding was also observed for Gal-GNP. Glc-, TetraMan-, and DiMan-GNPs were not
recognized by the sera’s IgG. Non-specific interactions of the secondary anti-mouse IgG with the GNPs were excluded performing
the GNP-ELISA in the absence of 2G12. Sera of mice immunized with saline were used as negative control. Differences between
sera from immunized mice and control samples are significant, as indicated with one (p<0.05) or two asterisks (p<0.01); (B) ELISA
plate coated with 25 µg/mL of TetraPn-GNP carrying S. pneumoniae or Glc-GNP (control) were used to determine the detection limit
for anti-TetraPn antibodies in mice sera. GNP-ELISA was able to detect antibodies up to 1:50,000 dilutions of sera. Differences
between TetraMan-GNP and Glc- GNP are significant, as indicated with one (p<0.05) or two asterisks (p<0.01).
doi: 10.1371/journal.pone.0073027.g003
A Solid Phase Assay Based on Glyconanoparticles
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e73027
coated with 25 µg/mL of TetraPn-GNP (Figure 3B). The OD at
450 nm coming from the specific anti-carbohydrate IgGs
binding was detected up to 1:50,000 dilution. In comparison to
the classical ELISA used in our previous work [19] a ~3,000-
fold increase of detection was achieved by this new method
based on GNPs (Figure 4, and Figure S5 in File S1). The
classical ELISA for the detection of anti-carbohydrate was able
to detect IgGs in mice sera from l: 10 to 1:50 sera dilution, with
OD ~ 0.65 at 1:10 dilution. Using the GNP-ELISA methodology
we were able to detect specific anti-carbohydrate IgGs from
1:10.000 to 1:50.000 sera dilution, with an OD ~ 0.65 at
1:30.000 dilution (Figure 4 and Figure S5 in File S1). These
results demonstrate that the GNP-ELISA represents a novel,
straightforward screening method for detecting anti-
carbohydrate antibodies evoked by carbohydrate-based
vaccines.
The estimated total protein concentration in the immunized
mice sera was ~20mg/mL as determined by UV absorbance at
280nm [29]. Purification of mice sera by Protein G-Sepharose
high performance columns, led to ~0.2 mg/mL of total IgGs in
the mice sera (Text S2 in File S2). From these results and from
the dilution we used in our work, ng/mL of anti-carbohydrate
antibodies were detected while with the classic approach (BSA-
ELISA) only μg/mL of antibodies were detected.
The method could be extended to screen the affinity of any
carbohydrate, once tailored onto the multivalent GNP
nanoplatform. The GNP-technique is more sensitive than
ELISA based on glycoconjugation to proteins, probably due to
the higher glycan density on the 3D surface of the gold
nanoclusters (Figure S5 in File S1). This new approach also
affords an easier and faster procedure to monitor the antibody
titers during animal immunization studies as the same GNP
construct can be used both for the immunization and for
screening the antibody titers in ELISA. The GNP-ELISA
approach may also allow multiple screening of complex
samples for the detection of anti-carbohydrate antibodies by
using GNPs displaying different carbohydrate antigens.
Figure 4.  Direct comparison between BSA-ELISA and GNP-ELISA for IgGs detection in mice.  At low sera dilution (dotted
blue lines, from 1:10 to 1:200) the BSA-ELISA (blue line, squares) gave a response from 0.7 to 0.1 OD, while the GNP-ELISA (blue
line, triangle) gave a saturated response around 4 OD. At high sera dilution (dark lines, from 1:10.000 to 1:100.000) the BSA-ELISA
(dark line, reverse triangle) was no able to detect IgGs (OD around zero), while the GNP-ELISA (dark line, rhombus) detected IgGs
(OD from 1.4 to 0.3) up to 1:50.000 diluted sera.
doi: 10.1371/journal.pone.0073027.g004
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Dendritic cells adhesion assay using GNP-ELISA
The application of the multivalent GNP-coated surface was
extended to an adhesion assay with human dendritic cells (DC)
to evaluate the potentiality of this new ELISA coating for
studying cellular carbohydrate-mediated interactions. DCs are
antigen-presenting cells that display calcium-dependent
glycan-binding proteins (C-type lectins) on their surface, which
function in the recognition and internalization of pathogens [30].
One of the C-type lectin expressed in DC is DC-SIGN
(Dendritic Cell Specific Intracellular Adhesion Molecule
Grabbing Non-integrin) with dual specificity for mannose- and
fucose-containing glycans [31,32]. To evaluate binding of DC to
different GNPs, ELISA wells were coated with Glc-GNP,
DiMan-GNP, and Gal-GNP. It has been previously shown that
DiMan-GNP inhibits gp120(CN54) binding to DC-SIGN in the
nanomolar range [18]. Binding of moDC was determined using
a calcium and magnesium containing buffer in the absence and
presence of ethylene glycol tetra acetic acid (EGTA) or the anti
DC-SIGN blocking mAbs AZN-D1 [33]. This antibody was
previously shown to block the DC internalization of fluorescent-
GNPs carrying oligomannosides [34]. The GNP-modified plate
was incubated with calcein-labeled monocyte-derived DC
(moDC) following a protocol commonly used to investigate the
binding of moDC with glycoconjugates [21]. The moDC showed
a specific carbohydrate-dependent binding to the selected
GNPs, as shown in Figure 5. DiMan-GNP exhibited the highest
affinity for moDC (around 40% binding), while a weak binding
(~15%) was detected for Gal-GNP. This low binding is in
agreement with the reported low adhesion of DC to PAA-
coupled galactose [21]. The significant signal detected for Glc-
GNP (30%) can be explained by the previous evidence that
glucose at high concentrations inhibits the binding of high-
mannose glycoproteins to DC-SIGN [35].
The presence of EGTA 3.75 mM blocked the binding of the
moDC to both DiMan-GNP and Glc-GNP, indicating the
involvement of calcium-dependent C-type lectins (Figure 5,
grey bars). Pre-treatment of moDC with AZN-D1 (10 μg/mL)
significantly decreases their binding to Glc-GNP and, in a less
extent, to DiMan-GNP. This result suggests that DC-SIGN is
involved in the binding of moDC to DiMan and Glc-GNPs.
DC-SIGN binding to GNPs
To extend the GNP-ELISA to other carbohydrate-binding
proteins, the binding of a recombinant chimera protein DC-
SIGN-Fc to different sugar-coated GNPs was tested (Figure 6).
DC-SIGN-Fc was produced in Chinese hamster ovary K1 cells
by co-transfection of DC-SIGN-Sig-pIgG1 Fc (20 μg) and
pEE14 (5 μg) vector. DC-SIGN-Fc consists of the extracellular
portion of DC-SIGN (residues 64 to 404) fused at the C-
terminus to a human IgG1/Fc fragment into the Sig-pIgG1-Fc
vector [36]. DC-SIGN-Fc bound to TetraMan-, DiMan- and
PentaMan-GNPs in the presence of calcium and magnesium
containing buffer (TMS). The binding of DC-SIGN to DiMan-
GNP, TetraMan and PentaMan-GNPs was very high (OD>1) in
agreement with the carbohydrate-specificity of this lectin
[18,32]. Glc-GNP exhibited significant lower binding (OD~0.3)
than the mannoside GNPs, while no binding was detected for
Gal-GNP (OD<0.1) and BSA. No binding was detected in PBS.
This result indicates that DC-SIGN is involved in the adhesion
of DC to the carbohydrate-modified plate and validate the
Figure 5.  Dendritic cells adhesion assay using GNP-ELISA.  Dendritic cells show different carbohydrate-affinity. Binding of
moDC to GNPs in calcium and magnesium containing buffer, was determined using plate adhesion assay in the presence or
absence of EGTA (3.75 nM) or anti-DC-SIGN antibody AZN-D1 (10 μg/mL). These experiments were performed at least four times
with similar results. Each experiment was performed in triplicate. Error bars indicate standard deviations. The binding to the GNPs
was significantly decreased when treated with EGTA or AZN-D1, as indicated with one (p<0.05) or two asterisks (p<0.01).
doi: 10.1371/journal.pone.0073027.g005
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GNP-ELISA for lectin detection and interactions. The selective
adhesion of DCs and recombinant lectin to GNPs confirms also
the coating of the ELISA surface with the multivalent GNPs and
indicates that GNP-ELISA can be used in solid-phase assays
to explore glycan-binding properties of lectins as well as whole
cells. The binding of bacteria [37–39] and mammalian cells [40]
to carbohydrates have been also probed in microarray systems
and our new ELISA approach can contribute to cellular studies
on solid-phase.
Conclusions
A new fast and sensitive method (GNP-ELISA) for the
detection of anti-carbohydrates antibodies and other glycan-
binding proteins has been developed by using multivalent and
high molecular weight GNPs as solid-phase coating. GNPs are
three-dimensional systems that allow a high valence in the
presentation of selected glycans (up to 100 copies per
nanoparticle) on a 2 nm gold nanoclusters. This high
concentration of glycans in a small surface could be
responsible for the high sensitivity of our assay. The possibility
of varying density and type of carbohydrate antigen on the
nanoparticles [41] makes the GNP-ELISA a versatile and
sensitivity method for multiplex detection of carbohydrate-
binding partner comparable to printed glycan-array. We first
showed the selectivity of GNP-ELISA for detecting the
interaction between a tetramannoside of the high-type
mannose glycan expressed on HIV glycoprotein gp120 and the
human antibody 2G12 at the nM range. Furthermore, we have
successfully used GNP-ELISA to highly improve the detection
(~3,000-fold) of specific IgGs against S. pneumoniae in mice
sera respect to the BSA-based ELISA. Finally, we showed that
the GNP-ELISA can be used in solid phase cellular binding
assays, as demonstrated by the selective binding of human
moDC and the lectin DC-SIGN on the multivalent surface. Gold
nanoparticles have previously been used in immunosensing by
profiting of the unique physical properties of metallic
nanoclusters [42]. The simplicity, the high sensitivity and the
versatility of the GNP-ELISA method, represents a new
approach to basic studies of protein-carbohydrate interactions
that can be especially useful for vaccination studies and clinical
identification of biomarkers.
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Figure 6.  DC-SIGN-Fc binding to GNPs.  Binding was determined using GNPs-ELISA in PBS and in calcium and magnesium
containing buffer (TMS). These experiments were performed in triplicate at least three times with similar results. Error bars indicate
standard deviations.
doi: 10.1371/journal.pone.0073027.g006
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